Comparative Pharmacology
Head-to-head clinical analysis: LACOSAMIDE versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACOSAMIDE versus VIGAFYDE.
LACOSAMIDE vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."